Page last updated: 2024-11-02

pilsicainide and Cardiomegaly

pilsicainide has been researched along with Cardiomegaly in 1 studies

pilsicainide: structure given in first source
pilsicainide : A secondary carboxamide resulting from the formal condensation of the amino group of 2,6-dimethylaniline with the carboxy group of (tetrahydro-1H-pyrrolizin-7a(5H)-yl)acetic acid. It is a sodium channel blocker which is used as an antiarrhythmic drug for the management of atrial tachyarrhythmias in Japan.

Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nakazato, Y1
Nakata, Y1

Other Studies

1 other study available for pilsicainide and Cardiomegaly

ArticleYear
Images in cardiology: Successful treatment of atrial tachycardia-induced cardiomyopathy with pilsicainide.
    Heart (British Cardiac Society), 2001, Volume: 86, Issue:6

    Topics: Adolescent; Anti-Arrhythmia Agents; Cardiomegaly; Female; Humans; Lidocaine; Radiography; Stroke Vol

2001